These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33905294)

  • 21. Adverse outcome pathways (AOPs) for radiation-induced reproductive effects in environmental species: state of science and identification of a consensus AOP network.
    Tollefsen KE; Alonzo F; Beresford NA; Brede DA; Dufourcq-Sekatcheff E; Gilbin R; Horemans N; Hurem S; Laloi P; Maremonti E; Oughton D; Simon O; Song Y; Wood MD; Xie L; Frelon S
    Int J Radiat Biol; 2022; 98(12):1816-1831. PubMed ID: 35976054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse outcome pathways: opportunities, limitations and open questions.
    Leist M; Ghallab A; Graepel R; Marchan R; Hassan R; Bennekou SH; Limonciel A; Vinken M; Schildknecht S; Waldmann T; Danen E; van Ravenzwaay B; Kamp H; Gardner I; Godoy P; Bois FY; Braeuning A; Reif R; Oesch F; Drasdo D; Höhme S; Schwarz M; Hartung T; Braunbeck T; Beltman J; Vrieling H; Sanz F; Forsby A; Gadaleta D; Fisher C; Kelm J; Fluri D; Ecker G; Zdrazil B; Terron A; Jennings P; van der Burg B; Dooley S; Meijer AH; Willighagen E; Martens M; Evelo C; Mombelli E; Taboureau O; Mantovani A; Hardy B; Koch B; Escher S; van Thriel C; Cadenas C; Kroese D; van de Water B; Hengstler JG
    Arch Toxicol; 2017 Nov; 91(11):3477-3505. PubMed ID: 29051992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The integration of the adverse outcome pathway framework to radiation risk assessment.
    Chauhan V; Stricklin D; Cool D
    Int J Radiat Biol; 2021; 97(1):60-67. PubMed ID: 32397918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of a pharmacokinetic-driven computational fluid dynamics model to predict nasal extraction of hydrogen sulfide in rats and humans.
    Schroeter JD; Kimbell JS; Andersen ME; Dorman DC
    Toxicol Sci; 2006 Dec; 94(2):359-67. PubMed ID: 16984956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges in the quantification approach to a radiation relevant adverse outcome pathway for lung cancer.
    Stainforth R; Schuemann J; McNamara AL; Wilkins RC; Chauhan V
    Int J Radiat Biol; 2021; 97(1):85-101. PubMed ID: 32909875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic low-level hydrogen sulfide exposure and potential effects on human health: a review of the epidemiological evidence.
    Lewis RJ; Copley GB
    Crit Rev Toxicol; 2015 Feb; 45(2):93-123. PubMed ID: 25430508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks.
    Pittman ME; Edwards SW; Ives C; Mortensen HM
    Toxicol Appl Pharmacol; 2018 Mar; 343():71-83. PubMed ID: 29454060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing adverse outcome pathways on silver nanoparticle-induced reproductive toxicity via oxidative stress in the nematode Caenorhabditis elegans using a Bayesian network model.
    Jeong J; Song T; Chatterjee N; Choi I; Cha YK; Choi J
    Nanotoxicology; 2018 Dec; 12(10):1182-1197. PubMed ID: 30663905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical review of the human data on short-term nitrogen dioxide (NO2) exposures: evidence for NO2 no-effect levels.
    Hesterberg TW; Bunn WB; McClellan RO; Hamade AK; Long CM; Valberg PA
    Crit Rev Toxicol; 2009; 39(9):743-81. PubMed ID: 19852560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of gene × environment interactions on silver nanoparticle toxicity in the respiratory system: An adverse outcome pathway.
    Nicholas TP; Boyes WK; Scoville DK; Workman TW; Kavanagh TJ; Altemeier WA; Faustman EM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1708. PubMed ID: 33768701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An adverse outcome pathway for small intestinal tumors in mice involving chronic cytotoxicity and regenerative hyperplasia: a case study with hexavalent chromium, captan, and folpet.
    Bhat VS; Cohen SM; Gordon EB; Wood CE; Cullen JM; Harris MA; Proctor DM; Thompson CM
    Crit Rev Toxicol; 2020 Sep; 50(8):685-706. PubMed ID: 33146058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A strategy towards the generation of testable adverse outcome pathways for nanomaterials.
    Murugadoss S; Vinković Vrček I; Pem B; Jagiello K; Judzinska B; Sosnowska A; Martens M; Willighagen EL; Puzyn T; Dusinska M; Cimpan MR; Fessard V; Hoet PH
    ALTEX; 2021; 38(4):580-594. PubMed ID: 34008034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity.
    Bal-Price A; Meek MEB
    Pharmacol Ther; 2017 Nov; 179():84-95. PubMed ID: 28529068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor.
    Becker RA; Patlewicz G; Simon TW; Rowlands JC; Budinsky RA
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):172-90. PubMed ID: 26145830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse outcome pathway (AOP) development I: strategies and principles.
    Villeneuve DL; Crump D; Garcia-Reyero N; Hecker M; Hutchinson TH; LaLone CA; Landesmann B; Lettieri T; Munn S; Nepelska M; Ottinger MA; Vergauwen L; Whelan M
    Toxicol Sci; 2014 Dec; 142(2):312-20. PubMed ID: 25466378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
    Becker RA; Ankley GT; Edwards SW; Kennedy SW; Linkov I; Meek B; Sachana M; Segner H; Van Der Burg B; Villeneuve DL; Watanabe H; Barton-Maclaren TS
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):514-37. PubMed ID: 25863193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in intracellular pH play a secondary role in hydrogen sulfide-induced nasal cytotoxicity.
    Roberts ES; Wong VA; McManus BE; Marshall MW; Lancianese S; Dorman DC
    Inhal Toxicol; 2006 Mar; 18(3):159-67. PubMed ID: 16399658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydrogen sulfide (H2S) and sour gas effects on the eye. A historical perspective.
    Lambert TW; Goodwin VM; Stefani D; Strosher L
    Sci Total Environ; 2006 Aug; 367(1):1-22. PubMed ID: 16650463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A toxicity pathway-oriented approach to develop adverse outcome pathway: AHR activation as a case study.
    Jin Y; Feng M; Ma W; Wei Y; Qi G; Luo J; Xu L; Li X; Li C; Wang Y; Li D; Chen J; Zhao Y; Hou Y; Zhao Q; Jiang L; Xie M; Zheng Y; Yu D
    Environ Pollut; 2021 Jan; 268(Pt B):115733. PubMed ID: 33011576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Towards a systematic use of effect biomarkers in population and occupational biomonitoring.
    Zare Jeddi M; Hopf NB; Viegas S; Price AB; Paini A; van Thriel C; Benfenati E; Ndaw S; Bessems J; Behnisch PA; Leng G; Duca RC; Verhagen H; Cubadda F; Brennan L; Ali I; David A; Mustieles V; Fernandez MF; Louro H; Pasanen-Kase R
    Environ Int; 2021 Jan; 146():106257. PubMed ID: 33395925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.